Table 2 Primary outcome–modified Vesikari scale score by treatment and pathogen groups.

From: A randomized trial evaluating virus-specific effects of a combination probiotic in children with acute gastroenteritis

 

Overall N = 816 Mean (SD)

Probiotics N = 408 N; Mean (SD)

Placebo N = 408 N; Mean (SD)

Mean difference (95%CI)

P-value†

Negative (N = 299)

5.3 (4.2)

139; 5.1 (4.1)

160; 5.5 (4.3)

−0.410 (−1.379, 0.560)

0.407

Virus only (N = 451)

6.1 (4.6)

232; 6.3 (4.7)

219; 6.0 (4.4)

0.263 (−0.589, 1.114)

0.545

Bacteria only (N = 37)

7.7 (4.9)

17; 9.4 (5.3)

20; 6.4 (4.2)

2.990 (−0.160, 6.142)

0.063

Virus/bacteria co-detection (N = 19)

6.3 (4.8)

13; 6.2 (4.4)

6; 6.4 (5.9)

−0.180 (−5.544, 5.184)

0.948

Parasite (N = 6) or parasite/virus co-detection (N = 4)

6.7 (5.1)

7; 7.9 (5.6)

3; 3.8 (1.4)

4.038 (−0.730, 8.806)

0.097

  1. CI confidence interval, SD standard deviation.
  2. †Calculated employing the T-Test. The P-values reported are two-sided and unadjusted for multiple comparison. A P-value < 0.001 is statistically significant after adjustment for multiple comparison using Bonferroni method (n = 5).
Back to article page